57 related articles for article (PubMed ID: 1280620)
1. Properties of soluble CR2 in human serum.
Ling NR; Brown B
Immunobiology; 1992 Aug; 185(2-4):403-14. PubMed ID: 1280620
[TBL] [Abstract][Full Text] [Related]
2. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
3. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
[TBL] [Abstract][Full Text] [Related]
4. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
5. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.
Ling N; Hansel T; Richardson P; Brown B
Clin Exp Immunol; 1991 Apr; 84(1):16-22. PubMed ID: 1849806
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
7. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).
Siaw MF; Nemerow GR; Cooper NR
J Immunol; 1986 Jun; 136(11):4146-51. PubMed ID: 3009616
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
10. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.
Tsoukas CD; Lambris JD
Eur J Immunol; 1988 Aug; 18(8):1299-302. PubMed ID: 2970972
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of human IgE production by a subset of anti-CD21 monoclonal antibodies: requirement of a co-signal to modulate epsilon transcripts.
Henchoz S; Gauchat JF; Aubry JP; Graber P; Pochon S; Bonnefoy JY
Immunology; 1994 Feb; 81(2):285-90. PubMed ID: 7512529
[TBL] [Abstract][Full Text] [Related]
12. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
13. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
14. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
[TBL] [Abstract][Full Text] [Related]
15. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
16. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes.
Young LS; Dawson CW; Brown KW; Rickinson AB
Int J Cancer; 1989 May; 43(5):786-94. PubMed ID: 2469656
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
[TBL] [Abstract][Full Text] [Related]
18. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
19. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
20. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells.
Boackle SA; Morris MA; Holers VM; Karp DR
J Immunol; 1998 Dec; 161(12):6537-43. PubMed ID: 9862679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
